| Dr Joseph E Podolski, | |
|
71 Haynes St, Department Of Psychiatry, Manchester, CT 06040-4131 | |
| (860) 647-6831 | |
| Not Available |
| Full Name | Dr Joseph E Podolski |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 18 Years |
| Location | 71 Haynes St, Manchester, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225221732 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Waterbury Hospital | Waterbury, CT | Hospital |
| Bristol Hospital | Bristol, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bristol Hospital Multi-specialty Group, Inc. | 9032014758 | 114 |
| Prospect Ct Medical Foundation Inc | 7416244496 | 267 |
News Archive
libragen, a contract research organization dedicated to biocatalysis and metagenomics, has been a major contributor to the success of PolyModE (Polysaccharide Modifying Enzymes), a large collaborative research project funded by the European Community. The project, which began in 2009 and ended in April this year, looked at developing novel polysaccharide modifying enzymes for the optimized use of hydrocolloids as, for example, food additives or novel therapeutic agents in the food sciences and medical industries. Researchers focused on six industry-targeted hydrocolloids (alginates, carrageenans, chitosans, glycosaminoglycans, pectins, and xanthan gums) where traditional chemistry fails to achieve a certain desired modification.
Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Granisetron Hydrochloride Tablets USP, 1 mg (base) ("granisetron tablets").
A recent interview study has uncovered factors that may contribute to the use of potentially inappropriate medications (PIMs) at the end of life.
Researchers with the Institute of Urologic Oncology and the Department of Urology at UCLA have classified kidney cancer into several unique subtypes, a finding that will help physicians tailor treatment to individual patients and that moves cancer care one step closer to personalized medicine.
› Verified 1 days ago
| Entity Name | Hartford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407806391 PECOS PAC ID: 2567366016 Enrollment ID: O20031125000700 |
News Archive
libragen, a contract research organization dedicated to biocatalysis and metagenomics, has been a major contributor to the success of PolyModE (Polysaccharide Modifying Enzymes), a large collaborative research project funded by the European Community. The project, which began in 2009 and ended in April this year, looked at developing novel polysaccharide modifying enzymes for the optimized use of hydrocolloids as, for example, food additives or novel therapeutic agents in the food sciences and medical industries. Researchers focused on six industry-targeted hydrocolloids (alginates, carrageenans, chitosans, glycosaminoglycans, pectins, and xanthan gums) where traditional chemistry fails to achieve a certain desired modification.
Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Granisetron Hydrochloride Tablets USP, 1 mg (base) ("granisetron tablets").
A recent interview study has uncovered factors that may contribute to the use of potentially inappropriate medications (PIMs) at the end of life.
Researchers with the Institute of Urologic Oncology and the Department of Urology at UCLA have classified kidney cancer into several unique subtypes, a finding that will help physicians tailor treatment to individual patients and that moves cancer care one step closer to personalized medicine.
› Verified 1 days ago
| Entity Name | Hartford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770696643 PECOS PAC ID: 2567366016 Enrollment ID: O20031125000752 |
News Archive
libragen, a contract research organization dedicated to biocatalysis and metagenomics, has been a major contributor to the success of PolyModE (Polysaccharide Modifying Enzymes), a large collaborative research project funded by the European Community. The project, which began in 2009 and ended in April this year, looked at developing novel polysaccharide modifying enzymes for the optimized use of hydrocolloids as, for example, food additives or novel therapeutic agents in the food sciences and medical industries. Researchers focused on six industry-targeted hydrocolloids (alginates, carrageenans, chitosans, glycosaminoglycans, pectins, and xanthan gums) where traditional chemistry fails to achieve a certain desired modification.
Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Granisetron Hydrochloride Tablets USP, 1 mg (base) ("granisetron tablets").
A recent interview study has uncovered factors that may contribute to the use of potentially inappropriate medications (PIMs) at the end of life.
Researchers with the Institute of Urologic Oncology and the Department of Urology at UCLA have classified kidney cancer into several unique subtypes, a finding that will help physicians tailor treatment to individual patients and that moves cancer care one step closer to personalized medicine.
› Verified 1 days ago
| Entity Name | Bristol Hospital Multi-specialty Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649265679 PECOS PAC ID: 9032014758 Enrollment ID: O20031204000960 |
News Archive
libragen, a contract research organization dedicated to biocatalysis and metagenomics, has been a major contributor to the success of PolyModE (Polysaccharide Modifying Enzymes), a large collaborative research project funded by the European Community. The project, which began in 2009 and ended in April this year, looked at developing novel polysaccharide modifying enzymes for the optimized use of hydrocolloids as, for example, food additives or novel therapeutic agents in the food sciences and medical industries. Researchers focused on six industry-targeted hydrocolloids (alginates, carrageenans, chitosans, glycosaminoglycans, pectins, and xanthan gums) where traditional chemistry fails to achieve a certain desired modification.
Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Granisetron Hydrochloride Tablets USP, 1 mg (base) ("granisetron tablets").
A recent interview study has uncovered factors that may contribute to the use of potentially inappropriate medications (PIMs) at the end of life.
Researchers with the Institute of Urologic Oncology and the Department of Urology at UCLA have classified kidney cancer into several unique subtypes, a finding that will help physicians tailor treatment to individual patients and that moves cancer care one step closer to personalized medicine.
› Verified 1 days ago
| Entity Name | Natchaug Hospital, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295811321 PECOS PAC ID: 5395648737 Enrollment ID: O20040202000008 |
News Archive
libragen, a contract research organization dedicated to biocatalysis and metagenomics, has been a major contributor to the success of PolyModE (Polysaccharide Modifying Enzymes), a large collaborative research project funded by the European Community. The project, which began in 2009 and ended in April this year, looked at developing novel polysaccharide modifying enzymes for the optimized use of hydrocolloids as, for example, food additives or novel therapeutic agents in the food sciences and medical industries. Researchers focused on six industry-targeted hydrocolloids (alginates, carrageenans, chitosans, glycosaminoglycans, pectins, and xanthan gums) where traditional chemistry fails to achieve a certain desired modification.
Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Granisetron Hydrochloride Tablets USP, 1 mg (base) ("granisetron tablets").
A recent interview study has uncovered factors that may contribute to the use of potentially inappropriate medications (PIMs) at the end of life.
Researchers with the Institute of Urologic Oncology and the Department of Urology at UCLA have classified kidney cancer into several unique subtypes, a finding that will help physicians tailor treatment to individual patients and that moves cancer care one step closer to personalized medicine.
› Verified 1 days ago
| Entity Name | Manchester Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457399198 PECOS PAC ID: 4486647534 Enrollment ID: O20040406000161 |
News Archive
libragen, a contract research organization dedicated to biocatalysis and metagenomics, has been a major contributor to the success of PolyModE (Polysaccharide Modifying Enzymes), a large collaborative research project funded by the European Community. The project, which began in 2009 and ended in April this year, looked at developing novel polysaccharide modifying enzymes for the optimized use of hydrocolloids as, for example, food additives or novel therapeutic agents in the food sciences and medical industries. Researchers focused on six industry-targeted hydrocolloids (alginates, carrageenans, chitosans, glycosaminoglycans, pectins, and xanthan gums) where traditional chemistry fails to achieve a certain desired modification.
Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Granisetron Hydrochloride Tablets USP, 1 mg (base) ("granisetron tablets").
A recent interview study has uncovered factors that may contribute to the use of potentially inappropriate medications (PIMs) at the end of life.
Researchers with the Institute of Urologic Oncology and the Department of Urology at UCLA have classified kidney cancer into several unique subtypes, a finding that will help physicians tailor treatment to individual patients and that moves cancer care one step closer to personalized medicine.
› Verified 1 days ago
| Entity Name | Prospect Rockville Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205283538 PECOS PAC ID: 4880988211 Enrollment ID: O20160913001880 |
News Archive
libragen, a contract research organization dedicated to biocatalysis and metagenomics, has been a major contributor to the success of PolyModE (Polysaccharide Modifying Enzymes), a large collaborative research project funded by the European Community. The project, which began in 2009 and ended in April this year, looked at developing novel polysaccharide modifying enzymes for the optimized use of hydrocolloids as, for example, food additives or novel therapeutic agents in the food sciences and medical industries. Researchers focused on six industry-targeted hydrocolloids (alginates, carrageenans, chitosans, glycosaminoglycans, pectins, and xanthan gums) where traditional chemistry fails to achieve a certain desired modification.
Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Granisetron Hydrochloride Tablets USP, 1 mg (base) ("granisetron tablets").
A recent interview study has uncovered factors that may contribute to the use of potentially inappropriate medications (PIMs) at the end of life.
Researchers with the Institute of Urologic Oncology and the Department of Urology at UCLA have classified kidney cancer into several unique subtypes, a finding that will help physicians tailor treatment to individual patients and that moves cancer care one step closer to personalized medicine.
› Verified 1 days ago
| Entity Name | Prospect Ct Medical Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144677568 PECOS PAC ID: 7416244496 Enrollment ID: O20160919001322 |
News Archive
libragen, a contract research organization dedicated to biocatalysis and metagenomics, has been a major contributor to the success of PolyModE (Polysaccharide Modifying Enzymes), a large collaborative research project funded by the European Community. The project, which began in 2009 and ended in April this year, looked at developing novel polysaccharide modifying enzymes for the optimized use of hydrocolloids as, for example, food additives or novel therapeutic agents in the food sciences and medical industries. Researchers focused on six industry-targeted hydrocolloids (alginates, carrageenans, chitosans, glycosaminoglycans, pectins, and xanthan gums) where traditional chemistry fails to achieve a certain desired modification.
Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Granisetron Hydrochloride Tablets USP, 1 mg (base) ("granisetron tablets").
A recent interview study has uncovered factors that may contribute to the use of potentially inappropriate medications (PIMs) at the end of life.
Researchers with the Institute of Urologic Oncology and the Department of Urology at UCLA have classified kidney cancer into several unique subtypes, a finding that will help physicians tailor treatment to individual patients and that moves cancer care one step closer to personalized medicine.
› Verified 1 days ago
| Entity Name | Prospect Manchester Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316394638 PECOS PAC ID: 9234423625 Enrollment ID: O20160926000570 |
News Archive
libragen, a contract research organization dedicated to biocatalysis and metagenomics, has been a major contributor to the success of PolyModE (Polysaccharide Modifying Enzymes), a large collaborative research project funded by the European Community. The project, which began in 2009 and ended in April this year, looked at developing novel polysaccharide modifying enzymes for the optimized use of hydrocolloids as, for example, food additives or novel therapeutic agents in the food sciences and medical industries. Researchers focused on six industry-targeted hydrocolloids (alginates, carrageenans, chitosans, glycosaminoglycans, pectins, and xanthan gums) where traditional chemistry fails to achieve a certain desired modification.
Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Granisetron Hydrochloride Tablets USP, 1 mg (base) ("granisetron tablets").
A recent interview study has uncovered factors that may contribute to the use of potentially inappropriate medications (PIMs) at the end of life.
Researchers with the Institute of Urologic Oncology and the Department of Urology at UCLA have classified kidney cancer into several unique subtypes, a finding that will help physicians tailor treatment to individual patients and that moves cancer care one step closer to personalized medicine.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph E Podolski, 71 Haynes St, Department Of Psychiatry, Manchester, CT 06040-4131 Ph: (860) 647-6831 | Dr Joseph E Podolski, 71 Haynes St, Department Of Psychiatry, Manchester, CT 06040-4131 Ph: (860) 647-6831 |
News Archive
libragen, a contract research organization dedicated to biocatalysis and metagenomics, has been a major contributor to the success of PolyModE (Polysaccharide Modifying Enzymes), a large collaborative research project funded by the European Community. The project, which began in 2009 and ended in April this year, looked at developing novel polysaccharide modifying enzymes for the optimized use of hydrocolloids as, for example, food additives or novel therapeutic agents in the food sciences and medical industries. Researchers focused on six industry-targeted hydrocolloids (alginates, carrageenans, chitosans, glycosaminoglycans, pectins, and xanthan gums) where traditional chemistry fails to achieve a certain desired modification.
Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Granisetron Hydrochloride Tablets USP, 1 mg (base) ("granisetron tablets").
A recent interview study has uncovered factors that may contribute to the use of potentially inappropriate medications (PIMs) at the end of life.
Researchers with the Institute of Urologic Oncology and the Department of Urology at UCLA have classified kidney cancer into several unique subtypes, a finding that will help physicians tailor treatment to individual patients and that moves cancer care one step closer to personalized medicine.
› Verified 1 days ago
Dr. Allana R Lee, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Manchester, CT 06040 Phone: 860-646-1222 | |
Michael John Dewberry, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 444 Center St, Manchester, CT 06040 Phone: 860-646-3888 Fax: 860-645-4132 | |
Manpreet Kaur, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Manchester, CT 06040 Phone: 860-647-6827 Fax: 860-533-3452 | |
Dr. Constantine Zariphes, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 150 N Main St, Manchester, CT 06042 Phone: 860-533-3434 Fax: 860-647-6829 | |
Dr. Anees Ahmed, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 357 E Center St, #2, Manchester, CT 06040 Phone: 860-649-1178 | |
Jonathan L Chasen, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 444 Center St, Manchester, CT 06040 Phone: 860-646-3888 Fax: 860-645-4132 |